RxDoctor Payments DataLook up a doctor →

Steven Geister, MD

Internal Medicine · Tulsa, OKNPI 1265707327

Payments from drug & device makers

$16,625in general payments, 2019–2025

Across 1,098 payments — averaging $15.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Merck$1K
  • Pfizer$960
  • GSK$928
  • Amgen$802
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$16,576100%
  • Education$490%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)175$2,217
Novo Nordisk84$1,342
Merck83$1,055
Pfizer60$960
GSK76$928
Amgen51$802
Lilly USA, LLC53$782
AstraZeneca46$777
Johnson & Johnson48$680
Boehringer Ingelheim41$659
Astellas Pharma US Inc29$614
Abbott40$579
Novartis36$517
Bayer26$465
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC30$452
Takeda Pharmaceuticals U.S.A., Inc.25$445
Otsuka America Pharmaceutical, Inc.12$244
E.r. Squibb & Sons, L.L.C.14$205
Kowa Pharmaceuticals America, Inc.12$183
Amarin Pharma, Inc.10$173
Esperion Therapeutics, Inc.9$166
Eisai Inc.9$165
Exact Sciences9$136
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)6$134
Currax Pharmaceuticals LLC8$122
Sanofi-aventis U.S. LLC7$119
Daiichi Sankyo Inc.5$106
Axsome Therapeutics, Inc.4$103
Sumitomo Pharma America, Inc.4$91
Dexcom, Inc.4$91
Idorsia Pharmaceuticals US Inc5$87
Ironwood Pharmaceuticals, Inc6$86
Genentech USA, Inc.5$74
Biohaven Pharmaceuticals, Inc.5$73
Biogen4$72
Almatica Pharma LLC4$72
Avanir Pharmaceuticals, Inc.4$69
Lundbeck LLC3$66
Boston Scientific4$64
Antares Pharma, Inc.4$59
Biohaven Pharmaceutical Holding Company Ltd.4$56
Scilex Pharmaceuticals Inc.4$54
Phathom Pharmaceuticals, Inc.3$50
Nabriva Therapeutics, PLC3$49
Aimmune Therapeutics, Inc.2$47
Arbor Pharmaceuticals, Inc.3$43
Clarus Therapeutics Inc.3$43
Regeneron Healthcare Solutions, Inc.2$34
Inogen, Inc.2$27
Endo Pharmaceuticals Inc.2$26
Ultragenyx Pharmaceutical Inc.1$24
Corium, LLC1$23
Seqirus USA Inc1$19
Xeris Pharmaceuticals, Inc.1$18
Medicure Pharma Inc.1$17
Intra-sana Laboratories1$14
Paratek Pharmaceuticals, Inc.1$14
Nestle Healthcare Nutrition Inc.1$12
Aytu Biopharma, Inc.1$12
Shire North American Group Inc1$11

How this compares

$16,625 in reported general payments places this provider in the 95th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$101,798
Medicare patients
472
Services billed
2,068

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban243$211,018
Trelegy ElliptaFluticasone/Umeclidin/Vilanter186$123,332
OzempicSemaglutide80$97,089
MounjaroTirzepatide82$94,230
XareltoRivaroxaban74$71,772
JardianceEmpagliflozin65$59,380
EntrestoSacubitril/Valsartan60$55,572
MyrbetriqMirabegron75$43,631
FarxigaDapagliflozin Propanediol54$33,391
TrulicityDulaglutide11$27,065
Synjardy XrEmpagliflozin/Metformin Hcl28$25,719
Soliqua 100-33Insulin Glargine/Lixisenatide30$25,385
TrintellixVortioxetine Hydrobromide16$21,842
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$19,399
Trijardy XrEmpaglifloz/Linaglip/Metformin24$18,464

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$960$216,206260 claims
GSKTrelegy Ellipta, Breo Ellipta$928$132,881210 claims
Lilly USA, LLCMounjaro, Trulicity$782$121,29593 claims
Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr$659$103,564117 claims
Novo NordiskOzempic$1,342$97,08980 claims
Johnson & JohnsonXarelto$680$71,77274 claims
NovartisEntresto$517$55,57260 claims
AstraZenecaFarxiga, Breztri Aerosphere$777$52,79086 claims
Astellas Pharma US IncMyrbetriq$614$43,63175 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$119$25,38530 claims
MerckJanuvia, Verquvo$1,055$25,36025 claims
AbbVieLinzess, Synthroid$2,217$24,35890 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →